AMYLIN RECEPTOR AGONIST VS TRI-RECEPTOR INCRETIN AGONIST
the amylin agonist and the tri-receptor incretin agonist target body-composition research through completely different receptor systems. the amylin agonist is a long-acting amylin analog (amylin + calcitonin receptors · satiety pathway). the tri-receptor incretin agonist is a triple GLP-1 + GIP + glucagon agonist (incretin + thermogenesis pathway). the amylin agonist is most commonly studied in combination with the long-acting GLP-1 agonist as CagriSema.
Long-acting amylin analog · investigational
GLP-1 / GIP / Glucagon · investigational class
SIDE BY SIDE
WHICH IS BETTER · BY GOAL
Phase 2 the tri-receptor incretin agonist at the 12 mg arm reached LS-mean -24.2% body-weight reduction at 48 weeks. the amylin agonist monotherapy reached -10.8% at 26 weeks in its Phase 2.
the amylin agonist was developed specifically as a satiety complement to the long-acting GLP-1 agonist. The CagriSema combination (Frias 2023 Lancet, PMID 37364590) outperforms either monotherapy in T2D + obesity Phase 2.
Amylin/calcitonin agonism covers a satiety pathway that incretin agonists do not engage directly. For receptor-system breadth in a research panel, the amylin agonist adds a non-overlapping mechanism.
the tri-receptor incretin agonist is a single peptide engineered to engage three receptors. the amylin agonist is typically studied as the second component of a two-peptide combination (CagriSema).
STACKING NOTE
CagriSema (the amylin agonist + the long-acting GLP-1 agonist) is the established combinatorial framing for the amylin agonist. There is no published research stacking the amylin agonist with the tri-receptor incretin agonist; combining multiple body-composition agonists is not supported by published clinical trials.
SOURCED FROM GIGACOMPOUNDS
Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.